RxDoctor Payments Data

Heather Garrett

Family · Huntingdon, TNNPI 1750390399

Payments from drug & device makers

$1,142in general payments, 2019–2025

Across 58 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$420
  • AbbVie$266
  • Amgen$107
  • Lilly USA, LLC$74
  • Radius Health, Inc.$67
  • Astellas Pharma US Inc$50
  • plus $158 from 6 others

What the payments were for

  • Travel & lodging$182%
  • Food & beverage$1,07995%
  • Education$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,142 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$54,927
Medicare patients
144
Services billed
1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$124,474
JardianceEmpagliflozin46$33,630
MounjaroTirzepatide31$28,896
EliquisApixaban44$27,732
RybelsusSemaglutide24$27,406
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$17,656
XareltoRivaroxaban28$16,734
FarxigaDapagliflozin Propanediol20$14,556
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,865
LinzessLinaclotide14$11,761
JanuviaSitagliptin Phosphate19$11,746
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen370$6,832
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$6,827
TrintellixVortioxetine Hydrobromide13$6,142
TrulancePlecanatide11$5,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$420$151,880127 claims
AstraZenecaBreztri Aerosphere, Farxiga$40$32,21249 claims
Lilly USA, LLCMounjaro, Insulin Lispro$74$31,81254 claims
PfizerEliquis$29$27,73244 claims
AbbVieLinzess$266$11,76114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Huntingdon

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →